Policymaking based on CERs: Changes in costs are not the same as changes in benefits

Cost Effectiveness and Resource Allocation

Volumn 3, Issue , 2005, Pages

  Ament, Andre J H A ^a   Evers, Silvia M A A ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

PNEUMOCOCCUS VACCINE;

AGED; ARTICLE; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; ELDERLY CARE; HEALTH CARE COST; HEALTH CARE POLICY; HUMAN; LINEAR SYSTEM; MATHEMATICAL COMPUTING; MEDICAL DECISION MAKING; PREVENTIVE HEALTH SERVICE; QUALITY ADJUSTED LIFE YEAR; STREPTOCOCCUS INFECTION; UNITED KINGDOM; VACCINATION;

EID: 27744522290     PISSN: 14787547     EISSN: 14787547     Source Type: Journal    
DOI: 10.1186/1478-7547-3-3     Document Type: Article

References (19)

1. Drummond MF, O'Brien B, Stoddart GL, Torrance GW: Methods for the Economic Evaluation of Health Care Programmes Oxford University Press: Oxford; 1997.
2. Gold MR, Siegel JE, Russell LB, Weinstein MC: Cost-effectiveness in Health and Medicine Oxford University Press: Oxford; 1996.
3. Fine MJ, Smith MA, Carson CA, Meffe F, Sankey SS, Weissfeld LA, Detsky AS, Kapoor WN: Efficacy of pneumococcal vaccination in adults. A meta-analysis of randomized controlled trials. Arch Intern Med 1994, 154(23):2666-2677.
4. Fedson DS: The clinical effectiveness of pneumococcal vaccination: a brief review. Vaccine 1999, 17(Suppl 1):S85-90.
5. Hutchison BG, Oxman AD, Shannon HS, Lloyd S, Altmayer CA, Thomas K: Clinical effectiveness of pneumococcal vaccine. Meta-analysis. Can Fam Physician 1999, 45:2381-2393.
6. Nichol KL, Baken L, Wuorenma J, Nelson A: The health and economic benefits associated with pneumococcal vaccination of elderly persons with chronic lung disease. Arch Intern Med 1999, 159(20):2437-2442.
7. Shapiro ED, Berg AT, Austrian R, Schroeder D, Parcells V, Margolis A, Adair RK, Clemens JD: The protective efficacy of polyvalent pneumococcal polysaccharide vaccine. N Engl J Med 1991, 325(21):1453-1460.
8. Moore RA, Wiffen PJ, Lipsky BA: Are the pneumococcal polysaccharide vaccines effective? Meta-analysis of the prospective trials. BMC Fam Pract 2000, 1(1):.
9. Sisk JE, Riegelman RK: Cost-effectiveness of vaccination against pneumococcal pneumonia: an update. Ann Intern Med 1986, 104:79-86.
10. Plans-Rubio PP, Morales PG, Sanmarti LS: Coste-efectividad de la vacunacion neumococia en Cataluna. Rev Esp Salud Publica 1995, 69:409-417.
11. Jimenez FJ, Guallar P, Rubio C, Villasante P, Guallar E: Cost-effectiveness analysis of pneumococcal vaccination in the elderly Spanish population. Brit J of Med Econ 1996, 10:193-202.
12. Sisk J, Moskowitz AJ, Whang W, Lin JD, Fedson DS, McBean AM, Plouffe JF, Cetron MS, Butler JC: Cost-effectiveness of vaccination against pneumococcal bacteremia among elderly people. JAMA 1997, 278:1333-1339.
13. Baltussen R, Ament A, Leidl : Cost-effectiveness of vaccination against pneumococcal pneumonia in The Netherlands. Eur J of Public Health 1997, 7:153-161.
14. Postma MJ, Heijnen MA, Jager JC: Cost-effectiveness analysis of pneumococcal vaccination for elderly individuals in The Netherlands. Pharmacoeconomics 2001, 19(2):215-222.
15. Ament A, Baltussen R, Ortqvist A, Jöhnsson B, Verhaegen J, de Graeve D, Gaillat J, Rigaud-Bully C, Christie P, Salazar Cifre A, Vivas D, Loiseau C, Fedson D: The cost-effectiveness of pneumococcal vaccination for older people: a study in five western european countries. Clin Infect Dis 2000, 31:444-450.
16. Ament A, Fedson DS, Christie P: Pneumococcal vaccination and pneumonia: even a low efficacy is cost-effective. Clin Infect Dis 2001, 33:2078-2079.
17. Laupacis A, Feeny D, Detsky AS, Tugwell P X: How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. CMAJ 1992, 146(4):473-481.
18. Ament A, Baltussen R: Interpreting the results of economic evaluation; explicating the value of health. Health Economics 1997, 6:625-635.
19. Anderson JP, Bush JW, Chen M, Dolenc D: Policy space areas and properties of benefit-cost/utility analysis. JAMA 1986, 255(6):794-795.